Compensated Awareness Post View
Disclaimer
Horizon Pharma plc (HZNP) is “One to Watch”
Headquartered in Dublin, Ireland, Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical company whose aim is to improve lives with the recognition, development, acquisition, and commercialization of accessible medicines to meet a variety of patient medical needs. Horizon Pharma now markets nine key products through its orphan, rheumatology, and primary care business units.
Products include ACTIMMUNE®, Buphenyl®, Duexis®, KRYSTEXXA®, Migergot®, PENNSAID® 2%, Ravicti®, Rayos®, and Vimovo®. The-se products are used to reduce the frequency and severity of serious infections, treat patients with urea cycle disorders, relieve signs and symptoms of rheumatoid arthritis and osteoarthritis, decrease the risk of developing upper gastrointestinal ulcers, and treat patients with chronic gout, among other symptoms and diseases.
In October 2014, HZNP acquired PENNSAID® 2%, followed by Hyperion Therapeutics in May 2015. At the beginning of this year, the company completed the acquisition of Crealta Holdings LLC, which allowed it to expand its orphan business with KRYSTEXXA® (pegloticase), a biologic medicine for chronic, refractory gout.
In addition, Horizon Pharma recently entered into a definitive agreement with Raptor Pharmaceutical Corp. (NASDAQ: RPTP), through which HZNP will acquire all of the issued and outstanding shares of RPTP common stock for a cash payment of $9.00 per share. The transaction is expected to be completed by the end of 2016 and is estimated to be worth $800 million.
Horizon Pharma has approximately 890 global employees and operates across Ireland, Europe, and the United States. As of August 9, 2016, Horizon Pharma had a market capitalization of $3.60 billion. The company has seen steady growth in net sales and adjusted EBITDA. With net sales up from $74 million in 2013 to over $1 billion in 2015, HZNP expects to strengthen its focus on rare diseases while expanding further into Europe and other international markets.
For more information, visit the company’s website at www.HorizonPharma.comAbout QualityStocks
